Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.

Regulating the regulator: post-translational modification of RAS. Nat Rev Mol Cell Biol (2011) 2.81

Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov (2014) 2.77

Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45

Inhibition of Ras for cancer treatment: the search continues. Future Med Chem (2011) 2.14

Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood (2008) 1.15

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? Clin Cancer Res (2015) 1.14

A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res (2014) 1.11

Mechanism of farnesylated CAAX protein processing by the intramembrane protease Rce1. Nature (2013) 1.05

Modelling oncogenic Ras/Raf signalling in the mouse. Curr Opin Genet Dev (2009) 1.02

Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood (2010) 0.95

RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segments. Proc Natl Acad Sci U S A (2011) 0.94

Protein prenylation: unique fats make their mark on biology. Nat Rev Mol Cell Biol (2016) 0.85

Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases. J Biol Chem (2015) 0.80

8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. Bioorg Med Chem (2015) 0.76

ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03

Inducible gene targeting in mice. Science (1995) 21.22

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97

NF1 tumor suppressor gene function: narrowing the GAP. Cell (2001) 4.11

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem (1997) 3.21

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med (1995) 2.99

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42

Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem (1999) 1.90

Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56

ras and human tumors. Semin Cancer Biol (1992) 1.45

Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease. Blood (2006) 1.17

RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol (1999) 1.09

Inhibitors of the isoprenylated protein endoprotease. Biochemistry (1993) 0.97

Rap1 and SPA-1 in hematologic malignancy. Trends Mol Med (2004) 0.95

Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease. Biochemistry (1996) 0.91

Hematologic effects of inactivating the Ras processing enzyme Rce1. Blood (2002) 0.88

Inhibition of K-ras-transformed rodent and human cancer cell growth via induction of apoptosis by irreversible inhibitors of Ras endoprotease. Cancer Lett (1998) 0.85

Selective inhibition of ras-transformed cell growth by a novel fatty acid-based chloromethyl ketone designed to target Ras endoprotease. Ann N Y Acad Sci (1999) 0.82

The knockout mouse project. Nat Genet (2004) 7.80

Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab (2007) 5.04

Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell (2008) 5.04

BayGenomics: a resource of insertional mutations in mouse embryonic stem cells. Nucleic Acids Res (2003) 4.83

A public gene trap resource for mouse functional genomics. Nat Genet (2004) 3.96

Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab (2011) 3.49

Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res (2009) 3.44

The International Gene Trap Consortium Website: a portal to all publicly available gene trap cell lines in mouse. Nucleic Acids Res (2006) 3.40

Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30

ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol (2007) 3.27

Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26

Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. Cell Stem Cell (2008) 3.15

Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem (2006) 3.02

Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99

Laminopathies and the long strange trip from basic cell biology to therapy. J Clin Invest (2009) 2.94

Lamin B1 is required for mouse development and nuclear integrity. Proc Natl Acad Sci U S A (2004) 2.89

Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85

GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell Metab (2010) 2.75

A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science (2006) 2.71

A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest (2006) 2.39

Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A (2004) 2.39

Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23

Antioxidants accelerate lung cancer progression in mice. Sci Transl Med (2014) 2.23

Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation (2009) 2.20

Philadelphia (Ph) chromosome-positive thrombocythemia without features of chronic myeloid leukemia in peripheral blood: natural history and diagnostic differentiation from Ph-negative essential thrombocythemia. Ann Hematol (2004) 2.15

Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation (2006) 2.13

The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons. J Biol Chem (2008) 1.91

Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J Lipid Res (2008) 1.91

Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell (2010) 1.90

Abnormal development of the cerebral cortex and cerebellum in the setting of lamin B2 deficiency. Proc Natl Acad Sci U S A (2010) 1.89

Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science (2013) 1.88

Deficiencies in lamin B1 and lamin B2 cause neurodevelopmental defects and distinct nuclear shape abnormalities in neurons. Mol Biol Cell (2011) 1.86

Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell (2005) 1.85

The posttranslational processing of prelamin A and disease. Annu Rev Genomics Hum Genet (2009) 1.81

Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest (2004) 1.81

Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation (2011) 1.79

Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice. J Biol Chem (2008) 1.73

Chylomicronemia elicits atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol (2009) 1.72

Agpat6 deficiency causes subdermal lipodystrophy and resistance to obesity. J Lipid Res (2006) 1.68

Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation (2003) 1.68

Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. J Lipid Res (2009) 1.67

Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J Biol Chem (2005) 1.64

Agpat6--a novel lipid biosynthetic gene required for triacylglycerol production in mammary epithelium. J Lipid Res (2006) 1.62

Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010) 1.60

A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci U S A (2005) 1.59

Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology (2004) 1.56

Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56

Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase. J Biol Chem (2009) 1.54

Optogenetic stimulation of MCH neurons increases sleep. J Neurosci (2013) 1.53

AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. J Biol Chem (2008) 1.50

CD1d function is regulated by microsomal triglyceride transfer protein. Nat Med (2004) 1.49

Disruption of the phosphatidylserine decarboxylase gene in mice causes embryonic lethality and mitochondrial defects. J Biol Chem (2005) 1.48

Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci (2002) 1.48

GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest (2007) 1.47

Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency. J Biol Chem (2005) 1.43

Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc Natl Acad Sci U S A (2007) 1.41

Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest (2008) 1.40

Mouse models of the laminopathies. Exp Cell Res (2007) 1.40

Normal binding of lipoprotein lipase, chylomicrons, and apo-AV to GPIHBP1 containing a G56R amino acid substitution. Biochim Biophys Acta (2007) 1.39

Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation (2004) 1.37

ATP-citrate lyase deficiency in the mouse. J Biol Chem (2003) 1.35

An absence of both lamin B1 and lamin B2 in keratinocytes has no effect on cell proliferation or the development of skin and hair. Hum Mol Genet (2011) 1.35

Increased progerin expression associated with unusual LMNA mutations causes severe progeroid syndromes. Hum Mutat (2007) 1.34

Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta (2007) 1.33

Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature (2012) 1.30

Regulation of prelamin A but not lamin C by miR-9, a brain-specific microRNA. Proc Natl Acad Sci U S A (2012) 1.26

An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria. Hum Mol Genet (2010) 1.26

Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem (2010) 1.24

The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-gamma. Mol Endocrinol (2008) 1.23

Adipose subtype-selective recruitment of TLE3 or Prdm16 by PPARγ specifies lipid storage versus thermogenic gene programs. Cell Metab (2013) 1.22

Cell nuclei spin in the absence of lamin b1. J Biol Chem (2007) 1.22

HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc Natl Acad Sci U S A (2007) 1.20

The arrestin domain-containing 3 protein regulates body mass and energy expenditure. Cell Metab (2011) 1.19

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. Elife (2013) 1.18

GPIHBP1, a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins. J Lipid Res (2008) 1.18

Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. J Biol Chem (2007) 1.17

Targeting Ras signaling through inhibition of carboxyl methylation: an unexpected property of methotrexate. Proc Natl Acad Sci U S A (2003) 1.17

Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer. Cancer Sci (2010) 1.16

Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood (2008) 1.15